No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Biotechnology
Genmab A/S, a biotechnology firm based in Copenhagen, Denmark, specializes in the discovery and development of innovative antibody-based treatments for various forms of cancer and other serious conditions. The company currently commercializes several key therapeutic antibodies. DARZALEX (daratumumab) is utilized in the treatment of multiple myeloma (MM), specific non-MM blood cancers, and AL amyloidosis. Other marketed offerings include teprotumumab for thyroid eye disease, ofatumumab, which addresses chronic lymphocytic leukemia (CLL) and multiple sclerosis, and Amivantamab for advanced or metastatic non-small cell lung cancer (NSCLC) as well as gastric or esophageal cancers. Genmab maintains an extensive and active development pipeline, featuring a broad range of experimental therapies. This includes GEN1047, tisotumab vedotin (targeting cervical, ovarian, and other solid cancers), and bispecific antibodies such as DuoBody-PD-L1x4-1BB and DuoBody-CD40x4-1BB, which are engineered for solid tumors. Epcoritamab is being developed for relapsed/refractory diffuse large B-cell lymphoma and CLL, while HexaBody-CD38 and DuoHexaBody-CD37 are designed to treat hematological malignancies. Further assets in the pipeline encompass Teclistamab, currently in Phase 2 clinical trials for vaso-occlusive crises, Camidanlumab tesirine for Hodgkin lymphoma and solid tumors, JNJ-64007957 and JNJ-64407564 for MM, PRV-015 for celiac disease, Mim8 for haemophilia A, and Lu AF82422 for multiple system atrophy. Additionally, the company is engaged in approximately 20 pre-clinical research programs. Strategic collaborations are a cornerstone of Genmab's operational model. It holds a commercial license and co-development agreement with Seagen Inc. for tisotumab vedotin. The company also partners with CureVac AG on the research and development of mRNA-based antibody products, with argenx for the discovery of novel therapeutic antibodies in immunology and oncology, and with AbbVie for the development of epcoritamab. Other notable collaborators include BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was established in 1999 and is headquartered in Copenhagen, Denmark.
www.genmab.comNo one on the platform currently holds GMAB.CO.
No tracked institution reports a position in GMAB.CO as of their last filing.
No one on the platform has traded GMAB.CO yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 10.7% | 19.9% | 23.0% | — | — | — |
| Rev. Growth % | -82.1% | -17.5% | ||||
| Profit Margin % | 25.9% | 32.2% | 40.9% | |||
| Free Cash Flow Margin % | 30.9% | 31.3% | 33.7% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $4.4B | +19.9% | $11.83 | $10.25–$15.03 | — | 12 |
| 2027 | $5.2B | +17.0% | $17.16 | $11.28–$23.75 | — | 13 |
| 2028 | $6.3B | +20.4% | $25.98 | $16.57–$34.86 | — | 15 |
| 2029 | $6.4B | +2.9% | $25.83 | $23.41–$28.10 | — | 9 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 5 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-06 | $23.36 | $31.78 | +36.0% |
| 2026-05-07 | $10.10 | $5.27 | -47.8% |
| 2026-02-17 | $17.89 | $3.14 | -82.4% |
| 2025-11-06 | $31.44 | $41.79 | +32.9% |
| 2025-08-07 | $25.51 | $34.65 | +35.8% |
| 2025-05-08 | $15.81 | $20.26 | +28.1% |
| 2025-02-12 | $22.26 | $58.84 | +164.3% |
| 2024-11-06 | $21.89 |
| $19.81 |
| -9.5% |
| +1.08% |
| $63.1B |
| — |
| GN.COGN Store Nord A/S | $94.48 | -0.55% | $13.8B | — |
| GUBRA.COGubra A/S | $290.20 | -2.22% | $4.8B | — |
Source: Financial Modeling Prep · peers by sector/industry